Discordant responses between brain metastases and extracranial tumors can arise from branched tumor evolution, underscoring the importance of profiling mutations to optimize therapy. However, the morbidity of brain biopsies limits their use. We investigated whether cell-free DNA (cfDNA) in CSF could serve as an effective surrogate marker for genomic profiling of intraparenchymal (IP) brain metastases. METHODS: CSF and blood were collected simultaneously from patients with progressive brain metastases undergoing a craniotomy or lumbar puncture. Mutations in both biofluids were measured using an error-suppressed deep sequencing method previously published by our group. Forty-three regions of 24 cancer-associated genes were assayed. RESULTS: This study enrolled 14 patients with either IP brain metastases (n = 12) or cytology-positive leptomeningeal disease (LMD, n = 2) and two controls with normal pressure hydrocephalus. Primary cancer types were lung, melanoma, renal cell, and colorectal. cfDNA was measurable in all sixteen samples of CSF. Cancer-associated mutations were found in the CSF of ten patients (eight with IP [67%] and two with LMD [100%]) and plasma of five patients (five with IP [42%] and none with LMD). All patients with plasma cfDNA had extracranial tumors. Among the five patients in the cohort who also had mutation data from time-matched brain metastasis tissue, four patients (80%) had matching mutations detected in CSF and brain, whereas only one patient (20%) had matching mutations detected in plasma and brain. CONCLUSION: The detection of mutational DNA in CSF is not restricted to LMD and was found in two thirds of patients with IP brain metastases in our cohort. Analysis of CSF can be a viable alternative to biopsy for detection of somatic mutations in brain metastases.
Discordant responses between brain metastases and extracranial tumors can arise from branched tumor evolution, underscoring the importance of profiling mutations to optimize therapy. However, the morbidity of brain biopsies limits their use. We investigated whether cell-free DNA (cfDNA) in CSF could serve as an effective surrogate marker for genomic profiling of intraparenchymal (IP) brain metastases. METHODS: CSF and blood were collected simultaneously from patients with progressive brain metastases undergoing a craniotomy or lumbar puncture. Mutations in both biofluids were measured using an error-suppressed deep sequencing method previously published by our group. Forty-three regions of 24 cancer-associated genes were assayed. RESULTS: This study enrolled 14 patients with either IP brain metastases (n = 12) or cytology-positive leptomeningeal disease (LMD, n = 2) and two controls with normal pressure hydrocephalus. Primary cancer types were lung, melanoma, renal cell, and colorectal. cfDNA was measurable in all sixteen samples of CSF. Cancer-associated mutations were found in the CSF of ten patients (eight with IP [67%] and two with LMD [100%]) and plasma of five patients (five with IP [42%] and none with LMD). All patients with plasma cfDNA had extracranial tumors. Among the five patients in the cohort who also had mutation data from time-matched brain metastasis tissue, four patients (80%) had matching mutations detected in CSF and brain, whereas only one patient (20%) had matching mutations detected in plasma and brain. CONCLUSION: The detection of mutational DNA in CSF is not restricted to LMD and was found in two thirds of patients with IP brain metastases in our cohort. Analysis of CSF can be a viable alternative to biopsy for detection of somatic mutations in brain metastases.
Authors: Ee Siang Choong; Serigne Lo; Martin Drummond; Gerald B Fogarty; Alexander M Menzies; Alexander Guminski; Brindha Shivalingam; Kathryn Clarke; Georgina V Long; Angela M Hong Journal: Eur J Cancer Date: 2017-02-23 Impact factor: 9.162
Authors: Elisa Benedettini; Lynette M Sholl; Michael Peyton; John Reilly; Christopher Ware; Lenora Davis; Natalie Vena; Dyane Bailey; Beow Y Yeap; Michelangelo Fiorentino; Azra H Ligon; Bo-Sheng Pan; Victoria Richon; John D Minna; Adi F Gazdar; Giulio Draetta; Silvano Bosari; Lucian R Chirieac; Bart Lutterbach; Massimo Loda Journal: Am J Pathol Date: 2010-05-20 Impact factor: 4.307
Authors: Priscilla K Brastianos; Scott L Carter; Gad Getz; William C Hahn; Sandro Santagata; Daniel P Cahill; Amaro Taylor-Weiner; Robert T Jones; Eliezer M Van Allen; Michael S Lawrence; Peleg M Horowitz; Kristian Cibulskis; Keith L Ligon; Josep Tabernero; Joan Seoane; Elena Martinez-Saez; William T Curry; Ian F Dunn; Sun Ha Paek; Sung-Hye Park; Aaron McKenna; Aaron Chevalier; Mara Rosenberg; Frederick G Barker; Corey M Gill; Paul Van Hummelen; Aaron R Thorner; Bruce E Johnson; Mai P Hoang; Toni K Choueiri; Sabina Signoretti; Carrie Sougnez; Michael S Rabin; Nancy U Lin; Eric P Winer; Anat Stemmer-Rachamimov; Matthew Meyerson; Levi Garraway; Stacey Gabriel; Eric S Lander; Rameen Beroukhim; Tracy T Batchelor; Jose Baselga; David N Louis Journal: Cancer Discov Date: 2015-09-26 Impact factor: 39.397
Authors: Sarah B Goldberg; Azeet Narayan; Adam J Kole; Roy H Decker; Jimmitti Teysir; Nicholas J Carriero; Angela Lee; Roxanne Nemati; Sameer K Nath; Shrikant M Mane; Yanhong Deng; Nitin Sukumar; Daniel Zelterman; Daniel J Boffa; Katerina Politi; Scott N Gettinger; Lynn D Wilson; Roy S Herbst; Abhijit A Patel Journal: Clin Cancer Res Date: 2018-01-12 Impact factor: 12.531
Authors: David E Piccioni; Achal Singh Achrol; Lesli A Kiedrowski; Kimberly C Banks; Najee Boucher; Garni Barkhoudarian; Daniel F Kelly; Tiffany Juarez; Richard B Lanman; Victoria M Raymond; Minhdan Nguyen; Judy D Truong; Annie Heng; Jaya Gill; Marlon Saria; Sandeep C Pingle; Santosh Kesari Journal: CNS Oncol Date: 2019-03-11